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 INTRODUCTION 
 
Diabetes mellitus, a clinical syndrome characterized by 
deficiency or insensitivity to insulin and exposure of organs to 
chronic hyperglycemia is the most common medical complication of 
pregnancy. 
 Preexisting diabetes affects approximately 1-3 pregnancies per 
1000 births. 
 Gestational diabetes is defined as carbohydrate intolerance of 
variable severity with onset or first recognition during pregnancy.  
This definition applies whether or not insulin is required for 
treatment. 
 GDM complicates 3-4% of all pregnancies globally and 90% 
of these  cases are definitely associated with a significantly increased  
maternal and  perinatal morbidity.  All complications associated with 
GDM are potentially preventable with early recognition of GDM, 
intense monitoring and proper treatment. 
 Moreover in view of the high prevalence of diabetes mellitus 
and its early onset among Indians, all pregnant women should be 
screened for GDM.  Hence an appropriate  method  for  screening of  
GDM has been much emphasized. 
 The importance of GDM is that two generations are at risk of 
developing diabetes in the future.  Women with a history of GDM 
are at increased risk of future diabetes, predominantly type 2 
diabetes as are their children.  Besides any abnormal glucose 
intolerance during pregnancy also has adverse fetal outcome.  
Increasing maternal carbohydrate intolerance in pregnant women 
without GDM is associated with a graded increase in adverse 
maternal & fetal outcomes. 
 India falls under moderately high risk group and hence need to 
undergo universal screening.  Hence this study is undertaken to 
know the incidence of GDM, need for universal screening & validity 
of the screening test. 
 
 
 
 
CARBOHYDRATE  METABOLISM  DURING  PREGNANCY. 
Pregnancy alters  carbohydrate  metabolism  but adaptation 
normally occurs without adverse effect on the mother or fetus.  In 
some the maternal response to these changes is abnormal which 
without careful management would lead to increased fetal risk. 
 Pregnancy is diabetogenic.  This is due to the increase in 
insulin resistance  that occurs during gestation.  Other reasons are 
increased lipolysis  and alterations in gluconeogenesis. 
 
DIABETOGENIC EFFECTS OF PREGNANCY. 
1. Insulin Resistance 
• Production of  human placental lactogen 
• Increased production of cortisol,  estriol and progesterone 
which have anti-insulin effects. 
• Increased insulin destruction by renal and placental 
insulinases. 
2. Increased lipolysis 
 The mother utilizes fat for her caloric needs and saves glucose 
for fetal needs. 
 
3. Changes in gluconeogenesis 
 The fetus preferentially utilizes alanine and other amino acids, 
depriving the mother of a major gluconeogenic  source. 
 As a result of the physiologic changes of pregnancy the normal 
fasting blood sugar is 65+9 mg/dl.  The mean non-fasting blood 
sugar level is 80+10 mg/dl. 
During the fed state. 
 During the first few hours  glucose absorbed from the gastro 
intestinal tract  provides for the metabolic needs of the brain and  
other organs.  The absorbed glucose in excess of these needs in used 
to rebuild fuel reservoirs in liver, muscle, fat and presumably in 
other tissues, synthesis  of glycogen  and triglycerides takes place.  
There is facilitated anabolism. 
During the fasted state. 
 The pregnant woman changes rapidly from a post prandial 
state characterized by elevated and sustained glucose levels to a 
fasting state characterized by decreased plasma glucose and amino 
acids such as alanine.  During  fasting  the plasma  concentrations  of  
Free  fatty acids, Triglycerides and  cholesterol are higher.  This 
pregnancy induced switch in fuels from glucose to lipids is known as 
accelerated starvation, certainly when fasting is prolonged in the 
pregnant woman these alterations are exaggerated and ketonemia 
rapidly appears. 
      So, there is facilitated anabolism in the fed state and accelerated 
starvation in the fasted state which characterize the maternal fuel 
adaptive changes during pregnancy. 
Fuel Metabolism in Diabetic Pregnancy and Gestational 
Diabetes 
Pederson’s hypothesis 
Maternal hyperglycemia 
   
Fetal hyperglycemia 
 
 Fetal pancreatic hyperplasia 
 
Fetal hyper insulinemia 
 
 
Macrosomia       Organomegaly    Increased       Decreased surfactant 
                   (Eg liver, Heart)         Erythropoiesis        production 
 
Traumatic vaginal   delivery          Neonatal 
              polycythemia         Hyaline  
membrane disease 
Blood Glucose and insulin relationship in the mother and fetus 
 In the normal pregnant woman there is a continuous demand 
by the fetus for glucose as an energy substrate and it crosses the 
placenta by facilitated diffusion.  During fasting maternal glucose 
may fall significantly but in diabetes glucose levels are usually 
maintained and may be high without insulin.   
The plasma glucose concentration of the fetus follows that of 
the mother closely, resulting hyperglycemia stimulates hypertrophy 
of  fetal pancreatic islet cells resulting in increased insulin release 
which results in macrosomia and organomegaly due to glycogen 
synthesis, increased protein synthesis  and deposition of fat. 
Effect of pregnancy on Diabetes. 
 The considerable effects on carbohydrate metabolism 
particularly the lowered renal threshold for glucose and the 
diminishing sensitivity to insulin as pregnancy advances render the 
control of diabetes more difficult,  so more insulin needed to achieve 
metabolic control.  Poor control increases the incidence of maternal 
and fetal complications and is the single most important factor 
influencing the outcome of pregnancy.  Careful plasma glucose 
control is mandatory because of the adverse effect of hyperglycemia 
and ketosis  on the fetus.  This is difficult and needs special attention 
in early pregnancy when nausea and vomiting are common or when 
infection of any kind occurs and also during labour. 
Other effects of pregnancy on diabetes are progression of 
diabetic retinopathy,  worsening of diabetic nephropathy,  increased 
risk of death for patients  with  diabetic  cardiomyopathy. 
Effect of Diabetes on the mother. 
1. Spontaneous  abortion  
Due to poor glycemic control in Ist trimester. 
2. Monilial vaginitis and vulvitis 
3. Pre eclampsia  
Affects 10-25% of all pregnant diabetics 
4. Infection 
Urinary tract infection, high incidence of 
chorioamnionitis  and post partum endometritis 
5. Poly hydramnios 
6. Post partum haemorrhage 
7. Caesarean section 
High incidence in pregnant diabetics 
 
Effects of diabetes on the fetus 
1. Congenital abnormalities 
Frequency of congenital abnormalities is increased in women 
with poorly controlled type I diabetes.  The commonest  are  those of 
cardiovascular, skeletal and central nervous system. 
2.  Macrosomia. 
Incidence of fetal macrosomia is increased in women with 
gestational and type II diabetes 
3. Hyaline membrane disease. 
Fetal hyper insulinemia may delay the maturation of surfactant 
production systems and particularly the synthesis of phosphatidyl 
glycerol and phosphatidyl choline.  Insulin interferes with normal 
timing of glucocorticoid induced pulmonary maturation in fetus. 
4. Unexplained fetal death. 
Hyperglycemia mediated chronic aberrations in transport of oxygen 
and fetal metabolities may account for unexplained  fetal deaths. 
Osmotically induced villous  edema led to impaired fetal oxygen 
transport. Fetal death may be due to placental insufficiency in 
association with  severe preeclampsia. 
 
5. Hypoglycemia 
6. Hyperviscosity syndrome 
7. Hypocalcemia 
8. Apnoea and bradycardia 
9. Traumatic delivery 
Diagnosis of gestational diabetes at the earliest becomes very 
significant as early diagnosis and management can reduce the 
maternal and fetal complications to a great extent. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
AIM OF STUDY 
 
1. To find the incidence of abnormal blood sugar and 
gestational diabetes mellitus (GDM) by routine screening 
with 50 gm glucose challenge test in antenatal patients. 
 
2. To evaluate the sensitivity and specificity of glucose 
challenge test and Random Blood glucose test. 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE: 
 In 1824 Bennewitz published the first case report of 
gestational diabetes. This formed the basis of his MD thesis 
‘Diabetes Mellitus:  A symptom of pregnancy’.  In addition to the 
classic symptoms and signs of thirst, polyuria and associated 
glycosuria, he described the death of a macrosomic fetus due to 
impacted shoulders.  The patient’s diabetes resolved completely after 
delivery,  but recurred in two subsequent pregnancies. 
 The most comprehensive review of diabetes in pregnancy in 
the pre-insulin era was,  however,  published in  1909 by J.Whitridge 
Williams,  of  the John Hopkins University in Baltimore.  He was 
careful to distinguish between physiological glycosuria  and  true 
diabetes and presented a review of 57 pregnancies between 1874 and 
1909 involving 34 woman.  The maternal mortality in this series was 
25% and only 51% of woman gave birth to a living child.   
 In 1921 Frederick Banting and Charles best with the help of 
skilled chemist J.B.Colip found out the therapeutic active insulin. 
 In 1922 Banting received a Nobel prize.  Since then this 
metabolic disorder has been studied extensively. 
 Screening for Gestational Diabetes should be universal (Hrish 
et  al 1992). 2,561 women subjected to Glucose Challenge Test 
(GCT).  In this study 470 were screen positive and they were 
subjected to 3 hour OGTT (O ‘Sullivans Criteria).  80 women were 
diabetic and strict control was ensured among them and there was no 
significant difference with women of this group and with normal 
pregnant women.   
 Hence screening should be universal.  In a study by Hughes et 
al and Agarwal et al 19957 found that selective screening would have 
failed to detect 43% of gestational diabetes 28% of them would have 
required insulin.  Patients with GDM are at increased risk for 
macrosomia (26% Vs 11%) LSCS (37% Vs15%) shoulder dystocia 
(90% Vs 2%).   
 Screening should be done early as this factor reduces perinatal 
mortality and morbidity (Semmler-K, Semmler-S and 62 Steindel et 
al 1990).  If this metabolic complication is determined and treated in 
a later phase of pregnancy there is a higher rate of complications.  In 
their study PIH was 29.7% preterm labor was 21.8% LSCS rate 
23.8% perinatal mortality 2.9% congenital anomalies 5-9% and 
macrosomnia 32.7%, the effect of glucose intolerance on pregnancy 
is so high that a screening measure was undertaken just to assess 
knowledge of Diabetes during pregnancy and was called DPKS 
(Diabetes in pregnancy knowledge screen) spirito et al and Ruggeiro 
et al 1990)66 
 10Coustan et al 1991 has drawn attention to an entity called 
Gestational Diabetes and it can be understood in terms of risk to the 
pregnancy and or risk to the mother.  As various criteria are used in 
various parts of the world a pregnancy specific criteria is to be used 
(Berger et al 1990).  In this study he has stated that glucose 
intolerance by glycosuria is unreliable and should be replaced by 
blood sugar (Screening), in the 24th to 28th week of gestation.   This 
detects 3% of patients with glucose intolerance.  High risk patients 
ideally should have their glucose checked earlier to conception, at 24 
weeks to 28 weeks and also in 32nd to 36th week.  Edelburg69 and 
Philip son et al in 1991 in their study have diagnosed 66% of 
diabetes in I trimester in a high risk population with 50g GCT.  
However Stephenson et al 199122 has done a critical review and has 
found only macrosomia is consistently associated with GDM.  The 
reference standard and the OGTT are problematic in that there are no 
standardized testing procedures or definitive criteria for diagnostic 
interpretation.  There is insufficient data to justify routine screening 
for GDM.  However GDM is a challenge for the future and glucose 
intolerance develops in women unable to compensate for the 
metabolic changes incurred by pregnancy (Heigh et al 1992). Hence 
agreed criteria has to be followed, Screening for GDM can be done 
by estimation of  blood or plasma glucose, Glycosylated 
hemoglobin, glycated proteins and even triglycerides (Knopp and 
Magee et al 1992)41. 
 Screening for GDM to be done using a 50g glucose without 
prior patient preparation. One hour later venous blood to be drawn 
for glucose estimation and is called the glucose challenge  test (GCT 
O ‘Sullivan’ et al) Threshold for further testing  may be chosen 
based on the goal of the screening programme either to maximize 
sensitivity by using a 130mg/dl or to increase the specificity at the 
sacrifice of some sensitivity by using a 140mg/dl cut off (Coustan et 
al 199314). 25Gabbe et al (1991).  In his study concluded that a 
plasma glucose level obtained 1 hour after a 50g GCT is the best 
GDM screening test.  Khan et al40 (1991) in his study did a 75g GCT 
and plasma glucose was determined 2 hours later.  Women who had 
abnormal screen earlier had the test repeated at 28-32 weeks 
gestation. Normal screen with a risk factor was 8.6% and subsequent 
follow up revealed 3.2% of GDM and 1.9% of impaired GTT.  The 
advantage in using this 75g is that patient with plasma value greater 
than 170mg need not undergo repeat GTT.  
70Lindenbaun et al and cohen et al in 1990 have compared 
values from capillary blood specimen obtained by means of a 
reflectance meter with that of venous sample after GCT and have 
found out that 90% of patients will not require lab studies which 
results in cost savings.  Scheduling patients for OGTT was easy and 
women were most impressed. 
 Screening has  also  been done with fasting plasma glucose 
values and OGTT44. Mamsen et al 1990 has screened women with 
fasting plasma glucose levels. If the values were > 4 mmol/1 75g 
OGTT was performed and the incidence of GDM was 1.2% and if 
fasting plasma glucose is used one should measure after 31st week of 
gestation as most cases of abnormal OGTT occurs at that time.  
59Sacks et al 1922 has used fasting plasma glucose and has found out 
that this assay performed better than one hour GCT. 
 8Coustan et al 1991 has reviewed all the strategies and has 
ultimately recommended universal screening with a 50g GCT16.  
Chua et al and Rotham et al 1993 have performed  a study with 50g 
GCT to establish the sensitivity and specificity and if the threshold 
of 140mg/dl is used diagnostic yield fell to 25.4%.  There is a 
progressive increase in sensitivity if GCT was performed after 24 
weeks without significant increase in specificity52. Neiser et al and 
constan  et al 1992 have repeated GCT for women who had values 
greater than or equal to 130mg/dl after an average of 4-6 weeks and 
have repeated OGTT for women who had only one abnormal value 
in OGTT after an average of 4-6 weeks.  Of this 34% turned out to 
be GDM patients.  Hence even one abnormal value on GTT denotes 
a significant risk for the development of GDM, Watson73 et al in 
1989 has rescreened screen –ve patients at 34 weeks and 8%  turned 
out to be screen +ve at 34 weeks. 
 Huisman and Dozy observed that HbA1 which is the 
glycosylated fraction of  Glycosylated haemoglobin was increased in 
diabetics.  In Diabetes Mellitus the level of HbA1C would be 
proportional to the integrated blood glucose level in the previous 7 to 
8 weeks a period approximating to the half-life of the average red 
blood cell shown by Gabbet et al in 1977. 
 HbA1C is formed by nonenzymatic  glycation of hemoglobin 
and is dependent on the mean plasma glucose concentrations and the 
life span of the red cell.  Normal non pregnant level is 5.7% and in 
gestational diabetes its 8.8%.  
Disadvantages of HbA1C is that both high and low values have 
been  reported in chronic renal failure and the level is significantly 
reduced in patients with reduced red cell life span e.g. anemia & 
hemolytic anemia’s and above all is costly.  Hence measurement of 
blood HbA1C is only an adjuvant. 
 Measurement of glycosylated blood proteins is established as a 
means of assessing long-term glucose control in DM.  
Different methods of estimation of glycosylated serum 
proteins were developed and one such assay is the fructosamine 
assay (Johnson et al in 1987). 71Glucose first condenses non 
enzymatically with the terminal amino group of the serum proteins 
to form an unstable aldimine.  This under goes an Amodori 
rearrangement to form a more stable ketoamine.  This ketoamine is 
usually termed fructosamine to its structural similarity to fructose. 
Serum fructosamine values correlate closely with those of glycated 
proteins (Lyold et al 1985) and are easily reproductive (Baker et al 
1985) 37. 
 In 1983 Roberts et al Baker et al designed a study to assess 
serum fructosamine as a screening  test for the detection of 
gestational diabetes. 
 However in a study by Roberts et al 199058 concluded that 
glucose load had a sensitivity of 81% in diagnosing GDM when 
compared with 50% for fructosamine.  Hence he concluded it’s not 
an useful screening test.   Fructosamine shows potential as an 
objective marker of short term control in evaluating the maternal 
glycemic state.  (Cafalu et al & chester etal 1990)12. Fructosamine 
has a limited value as a screening test for GDM particularly for the 
mild form of glucose intolerance (nasrat et al & 1991)35. 
 On the contrary (Narayanan et al 1991) an ideal lab test should 
accurately reflect short term Glucose changes.  An objective strategy 
for lab monitoring of GDM should include assays such as 
fructosamine and even the less sensitive HbA1C assay.  
 Fructosamine achieved 77.3% specificity and 79.4% 
sensitivity for  diagnosis of GDM compared to GIT.  (Haughes, 
1995)38.  As a screening test for GDM the role of fructosamine 
remains controversial with conflicting claims made by various 
investigators.   
 American college of obstetricians and Gynaecologist (ACOG 
technical bulletin 1986) has recommended screening  for gestational 
diabetes using 50g gms/1hour GCT for all pregnant women aged 30 
years or older and for women with risk factors.  Coustan et al (1989) 
found that current ACOG recommendations resulted in sensitivity of 
only 65% and universal screening using a threshold of 140 mg/dl at 
24-28 wks as recommended by second International Workshop 
(Diabetes 1985) had a sensitivity of only 90%  Kini et al (1996) 
opined that 50 gms GCT should be repeated in third trimester as it 
yields a  large no of gestational diabetics.  We confined our  study to 
single screening test at 24-28weeks as per current recommendations. 
 American Diabetes Association (ADA) recommends two step 
procedures for screening and diagnosis of diabetes in selective 
population. Compared with selective screening,  universal screening 
for GDM detects more cases and improves maternal and off spring 
prognosis.   
  Another area of concern is that among ethnic groups in South 
Asian countries the Indian women have the highest frequency of 
GDM.  Hence universal screening during pregnancy has become 
important in our country. 
 The incidence of gestational diabetes varies  between 3-12% 
depending upon the population sample and the diagnostic criteria 
(carpenter 1982).  Compared to European women, prevalence of 
gestational diabetes has increased eleven fold in women from the 
Indian sub continent (Dornhurst 1992).  In a study conducted by 
Bhattacharya, Awasthi (2001) in pregnant women,  overall incidence 
of gestational diabetes was 3.07%.   Among the Indian workers, 
Maheswari et al (1989) and kumar et al (1993) found the incidence 
of gestational diabetes to be 4.9% and 5.5% respectively. 
DIAGNOSIS 
 Early detection which aids in timely intervention is very 
important in pregnancy complicated by this metabolic disorder. 
HOW TO DETECT EARLY  
 Unfortunately as onset of gestational diabetes has no reliable 
signs or symptoms this can be detected only though the use of 
laboratory test which we call screening tests.  
SCREENING FOR DIABETES DURING PREGNANCY 
 The justification for screening is the increased risk of  
perinatal death amongst women who develop an abnormal GTT in 
pregnancy.  If screening is to be effective it must be comprehensive.  
It should be simple, reliable, cheap and easy to interpret.  Glycosuria 
alone is not significant. 
WHOM TO SCREEN? 
 An area of controversy is whether screening for diabetes 
during pregnancy should be routine or if it should be limited to 
patient at risk for diabetes during pregnancy. 
RISK FACTORS REQUIRING DIABETIC SCREENING  
(ARIAS)23 
1. Obesity 
2. Positive family history of diabetes (Sibling or parent) 
3. History of still birth, intra uterine death. 
4. History of delivery of a large infant (>4000g). 
5. Glycosuria 
6. History of unexplained neonatal death 
7. History of congenital anomaly, prematurity, pre-eclampsia 
poly hydramnios, traumatic delivery with associated 
neurologic disorder in the infant. 
8. Poor obstetric history 
9. Chronic hypertension 
10. Recurrent severe moniliasis & urinary tract infection 
11. Age 30 years 
12. History of gestational diabetes  or impaired glucose 
tolerance  in a previous pregnancy.    
About 40-60% of women  with GDM have no demonstrable risk 
factor.  So screening should be universal.  If only high-risk patients 
are screened, approximately 35% of gestational diabetic patients will 
not be discovered. 
WHEN TO SCREEN? 
 Gestational diabetes typically occurs in the later half of 
pregnancy and has no effect on embryonic growth and thus is not a 
cause of congenital defects (Joselin). Gestational diabetes is a 
problem of the third trimester and the late second trimester. 
Hyperglycemia commencing during the second trimester results in 
behavioral changes while that occurring during the third trimester 
causes only anthropometric changes in the fetus. American diabetes 
association suggests that all women be screened between gestational 
weeks 24 and 28. Patients at high risk may have the test earlier at 
first booking but if negative they should have the test repeated 
between 26 and 30 weeks. (DESWEIT) 
SCREENING FOR GDM 
Urine tests  -  Glycosuria 
Blood tests   
Fasting plasma glucose. 
 Random Blood glucose. 
 50 gm glucose challenge test. 
 75 gm glucose  tolerance test. 
 Fructosamine assay. 
 Glycosylated Hb. 
Glycosuria 
 The traditional method of waiting for glycosuria to appear has 
a low pick up rate and as such is of limited value. Sutherland  et al 
found that 11% of an unselected obstetric  population of 1418 
women had glycosuria at some time, but fewer than 1% of those 
with glycosuria had an  abnormal GTT. 
Non challenge Blood glucose tests. 
 Non challenge blood glucose tests involve measuring glucose 
levels in blood samples without challenging the subject with glucose 
solutions. 
Fasting plasma glucose . 
 Sacks et al and Daniele  at al have observed that measuring 
FPG is an easier screening procedure  and suggested a cut off value 
of 95 mg/dl for GDM.   Most cases have FPG values below the 
putative threshold.  If FPG is followed as a screening procedure no 
of pregnant women having GDM would be higher. For these reasons 
fasting glucose is not favoured by the WHO for diagnosing GDM. 
Random plasma glucose: 
 Random plasma glucose  measurement has been encouraged  
as a simple way to screen for abnormal glucose tolerance. A positive 
cut- off was taken as 6.4 mmol/l if the women were tested less than 
2hr after  a meal and 5.8 mmol /l if more than 2hr  after a meal. Data 
on sensitivity & specificity of this method of screening was 
subsequently obtained which showed this to be a poor method of 
screening. 
 
50 gm glucose challenge test: 
 50 gm of glucose is administered orally between 24-28 weeks 
at any time. Fasting is not required.  Venous plasma glucose is 
measured  1 hr later. 
 If the cut off-point is set at 140 mg/dl (7.8 mmol/L) 80% of 
women with GDM will be detected.  If this threshold for further 
testing is lowered to 130 mg/dl 90% of GDM cases will be detected.  
 If results of screening are positive, a 3 hour 100 gm OGTT 
should be carried  out at 24-28  weeks for early identification of 
GDM. If the results of screening are normal, it should be repeated at 
32-34 weeks especially in obese patients, elderly patients and 
women with risk factors for GDM. 
 A value of 200 mg/dl on screening is so likely to be associated 
with the diagnosis of GDM that the GTT need not be performed and 
treatment can be started. 50 gm GCT was found to be very sensitive 
in detection of gestational diabetes in high risk group. Coustan  et al 
found  that current ACOG  recommendations result in sensitivity of 
65%. Kini et al opined that 50 gm GCT should be repeated in 3rd  
trimester as  it  yields a large no of gestational diabetics. Due to the 
simplicity,  acceptability, sensitivity and cost effectiveness of GCT, 
it is the best method to detect gestational diabetes mellitus in high 
risk group. 
75 gm glucose tolerance test. 
 WHO recommends performing 2 hour 75 g OGTT and 
diagnosing GDM with a threshold plasma glucose concentration 
greater than 140 mg/dl (7.8 mmol/L) at 2 hours  similar to that of 
impaired glucose tolerance test in the non-pregnant.  This  method 
serves both as a one-step screening and diagnostic procedure and is 
easy to perform besides being economical. 
Fructosamine assay  
 It  is associated with glycemic control over the previous 1-3 
weeks possibly making it a more appropriate marker for gestational 
diabetes. However its sensitivity is too low for it to be used as a 
screening method for GDM. 
Glycosylated  hemoglobin: 
 Proteins react spontaneously with glucose to form 
glycosylated  derivatives. HbA1c serves  as a retrospective indicator 
of the average glucose concentration over the previous 8-10 wks. 
The HbA1c level  is more strongly correlated to preprandial  than  
postprandial glucose concentrations. In the third trimester however 
HbA1c levels may only reflect  mean glucose  values over the 
previous 2 weeks, presumably because of increased rates of 
erythropoiesis. HbA1c  is expressed as a percentage of the normal 
hemoglobin and the normal range is approximately 4% to 6%. 
 The use of HbA1c and glycosylated proteins has been 
extensively investigated as a simple one sample screening test with 
no preparation required. Unfortunately after initial enthusiastic  
reports, multiple studies have, perhaps not surprisingly, shown that 
the tests have poor specificity and sensitivity. 
Diagnosis of GDM 
 The diagnostic test for GDM is the oral GTT. In North  
America, the American Diabetes Association and National Diabetes 
Data group recommend a 100 g oral glucose challenge as the 
diagnostic test and a randomly administered 50g oral glucose 
challenge as the screening test. 
 100gm of oral glucose is administered in the morning after an 
overnight fast of 8-14 hours duration after 3 days of carbohydrate 
rich diet(i.e. unrestricted diet >150 gm of carbohydrate per day ) and 
unrestricted  physical activity. 
 The subject should remain seated  and should not smoke 
throughout the test. The fasting venous blood glucose samples  are 
taken at 1,2 & 3 hours. 
Criteria for the diagnosis of GDM with 100gm oral glucose (venous 
plasma mg/dl) 
Time O’Sullivan Normal diabetes 
data group (1979) 
Carpenter 
and coustan 
(1982) 
WHO 
 
Fasting 
1 hr 
2 hrs 
3 hrs 
90 
165 
145 
125 
105 
190 
165 
145 
95 
180 
155 
140 
>140 
 
>200 
 
 The diagnosis of GDM is established if any 2 or more values 
exceed the upper limit of normal.  
 If only one value is abnormal the patient cannot be diagnosed 
as having  GDM  although she is at high risk. They have insulin  
resistance comparable to patients with GDM and are more likely to 
deliver macrosomic  infants. 
 
 
 
Criteria for diagnosis of impaired glucose tolerance and 
diabetes with 75gm oral glucose (ADA) plasma (mg/dl) 
Time Normal 
tolerance 
Impaired glucose 
tolerance 
Diabetes 
Mellitus 
Fasting 
2hrs pp 
<110 
<140 
>110 - <126 
>140 - <200 
>126 
>200 
             
Impaired glucose tolerance is diagnosed if fasting level is 
between 110 - 125 mg/dl or 2 hours postprandial is between 140 – 
199 mg/dl. 
 Diabetes is diagnosed  if,  
 Fasting is > 126 mg/dl 
  2 hour PP is  > 200 mg/dl in plasma and 170 mg/dl in whole 
blood. 
 Venous whole blood values are 15 percent less than the plasma 
values. 
 Women with GDM are undoubtedly at increased risk for 
adverse obstetric and perinatal outcomes.  Good maternal and fetal 
outcomes result from early and meticulous prenatal and intranatal  
care. Thus all pregnant women should be screened for GDM  at least 
once during pregnancy irrespective of the presence or absence of 
risk factors and all detected GDM,  should  be closely monitored for 
strict glycaemic control throughout pregnancy for optimal neonatal 
outcome.  
 Hence based on the above data this study was designed to 
screen pregnant women universally for GDM. 50g GCT and random 
Blood glucose was performed on 200 pregnant  women belonging to 
24 to 28 weeks gestation.  For all screen positive cases, 3 hour 
OGTT with 100g glucose was performed.    
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
SELECTION OF CASES: 
1. 200 pregnant women in their 24-28 weeks of gestation were 
selected irrespective of parity, age and risk factors. 
2. All the 200 pregnant women had random blood glucose and 
GCT done. 
INCLUSION CRITERIA 
1. All women who were selected had clinical examination and 
when the gestation was between 24-28 weeks were included in 
this study. 
2. Women who were not sure of their last menstrual period and 
whose clinical examination was inappropriate ha an ultrasound 
examination and when the period of gestation was between 24-
28 weeks they were included. 
EXCLUSION CRITERIA 
1. Women who were not within 24-28 weeks of gestation were 
excluded from the study. 
2. Women who were already pre-gestational diabetes and proved 
gestational diabetics in their current conception were excluded. 
PLACE OF STUDY 
 Govt Rajaji Hospital, Madurai Medical College, Madurai. 
YEAR OF STUDY 
 2009 
NATURE OF STUDY 
 Prospective study 
METHOD 
 Pregnant women who were selected with the above criteria had 
their random blood glucose estimated and were given 50g glucose 
drink, without prior patient preparation.  Glucose given-Dextrose 
monohydrate D-glucose.  One hour later 2.5ml of venous blood was 
drawn in an oxalate and fluoride test tube and immediately handed 
over to our hospital laboratory.  Following the glucose drink patients 
were prohibited from further eating or drinking except water. 
ESTIMATION OF BLOOD GLUCOSE 
ORTHOTOLUIDINE METHOD 
 0.1ml plasma 
 5 ml of orthotoluidine reagent.  Boil for 8 minutes and take 
reading at 650nm in a calorimeter.  Glucose reacts with 
orthotoluidine in acid medium to give green color.  The blood sugar 
levels obtained by this method were also confirmed by enzyme 
method. 
ENZYME METHOD 
 Glucose is oxidized by glucose oxidase into gluconic acid and 
H2O2.  H2O2 in the presence of peroxidase (POD) oxidizes the 
chromogen 4 aminophenozone/phenolic compound to a red colored 
compound.  The intensity of the red color produced is proportional 
to the glucose concentration and is measured at 505nm (490-
530nm).  The final color is stable for two hours. 
glucose oxidase 
Glucose   + O2                                         gluconic acid + H2O2 
   H2O2 ===Î H2O+O 
          Nascent oxygen 
Chromogen (Colour less)          ===Î           coloured product 
 Venous blood is collected in a fluoride containing test tube.  
Plasma is preferred.  Sodium fluoride is added to prevent glycolysis. 
 All women who had blood sugar value of > 130 mg/dl or 140 
mg/dl were considered screen positive and were subjected to 3 hours 
100 gms OGTT within a week of screening. 
 
 
Statistical Tools  
 The information collected regarding all the selected cases were 
recorded in a Master Chart.  Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2008). 
Information Package (EPI 2008) 
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and ‘p’ values were calculated.  Kruskul 
Wallis chi-square test was used to test the significance of difference 
between quantitative variables and Yate’s test for qualitative variables.  
A’p’ value less than 0.05 is taken to denote significant relationship. 
 Sensitivity, specificity, accuracy, positive predictive value and 
negative predictive values were calculated using the following formulae 
and taking GTT as the Gold standard. 
 
Sensitivity   =  True positive  x 100 
     True positive + False negative 
 
Specificity   =  True negative  x 100 
     False positive + True negative 
 
Accuracy   = True Positive + True Negative 
      Total cases 
 
Positive predictive value =  True positive  x 100 
     True positive + False positive 
 
Negative predictive value =  True negative  x 100 
     True negative + False negative 
 
OBSERVATION AND RESULTS 
 
1. AGE DISTRIBUTION 
 
 
Age Group (in years) 
Cases 
No % 
17-20 33 16.5 
21-25 105 52.5 
26-30 52 26 
31-35 10 5 
  
Age of pts ranged from 18 - 35 years.  In our study 5% of the 
pts were more than 30 years among which one was a GDM Patient.  
No GDM patient had age less than 21 years.  Mean age of the patient 
under our study was 24.1 years. 
 
 
 
 
  
 
2.   EDUCATIONAL STATUS 
 
Literacy Non 
GDM 
% GDM % 
Illiterate 61 30.5 0 0 
Primary education 55 27.5 1 33.33 
High School education 73 36.5 2 66.66 
College education 8 4 0 0 
 
 Majority of non GDM pts had high school education. 
 
 
 
 
 
 
  
 
3.  SOCIOECONOMIC STATUS 
Socioeconomic 
status 
No of cases in non 
GDM patients 
% No of cases in 
patients with 
GDM 
% 
Group I     
Group II     
Group III 17 8.5 2 66.66 
Group IV 87 43.5 1 33.33 
Group V 93 46.5   
  
Majority of non GDM patients belonged to Group V 
 
 
 
 
 
 
 
  
4. PARITY 
 
 
Parity 
Cases 
No % 
Primi 80 40 
G2 89 44.5 
G3 20 10 
G4 10 5 
G5 1 0.5 
Total 200 100 
  
In our study majority of patients were primi and second 
gravida. 
 
 
  
5. BODY MASS INDEX. 
 
 
BMI 
Cases 
No % 
<18.5 43 22% 
18.5-24.9 127 63% 
25 - 29.9 (overweight) 28 14% 
30 and above (obese) 102 1% 
  
In our study mean BMI of the patients was 21.5.  All 3 GDM 
patients had BMI between 25 to 29.9 and belonged to over weight 
category. 
 
 
 
 
 
  
 
6. FAMILY H/O DIABETES 
  
Family History No of cases in 
200 pregnant 
women 
% No of cases 
in pts with 
GDM 
% 
Father DM 13 6.6 1 33.33 
Mother DM 9 4.6 1 33.33 
Both parents DM 2 1   
No of patients with 
Family h/o DM 
24 12.18 2 66.66 
  
Among patients with GDM, 1 had family h/o mother with DM, 
1 had family h/o father with DM.  In our study family h/o Diabetes 
mellitus was present in 66% of patients with GDM. 
 
 
 
  
7. RISK FACTORS IN PRESENT PREGNANCY 
 
Risk of Factors No of cases in non 
GDM pts 
% No of cases in 
pts with GDM 
% 
Overweight, obese 30 15% 3 100 
H/O Recurrent UTI 3 1.6% 1 33.33 
H/O moniliasis 2 1.2% 1 33.33 
PIH 16 8 2 66.66 
Hydramnios 7 3.5 2 66.66 
Glycosuria 20 10 3 100 
Congenital 
malformation 
5 2.5 -  
 
Among GDM patients, all 3 was overweight 2 had PIH, 2 had 
hydramnios, all 3 had glycosuria, 1 had h/o Recurrent UTI, 1 had h/o 
moniliasis.  The same patient had more than one risk factor. 
 
 
  
8. RISK FACTORS IN PAST PREGNANCY. 
 
Risk  Factors 
No of cases in 
non GDM pts 
% No of cases in 
pts with GDM 
% 
H/O spontaneous 
abortion 
25 12.6 1 33.33
H/O delivery of a baby 
with macrosomia 
8 4   
H/O sudden IUD 3 1.5 1 33.33
H/O preterm delivery - -   
H/O still birth 1 0.5   
H/O instrumental 
delivery 
2 1   
H/O unexplained 
neonatal death 
3 1.5   
H/O previous GDM or 
IGT 
- -   
H/O previous PIH - - 1 33.33
H/O previous Babies 
with congenital 
anomalies 
1 0.5   
  
Among GDM patients one had h/o spontaneous abortion, h/o 
sudden IUD and h/o PIH in her previous pregnancy. 
9. DISTRIBUTION OF BLOOD GLUCOSE VALUES IN GCT 
AND  RANDOM BLOOD GLUCOSE 
Blood glucose levels 
(Range) 
GCT RBG 
No % No % 
61-70 
71-80 
81-90 
91 -  100 
101-110 
111-120 
121-130 
131-140 
141-150 
151-160 
161-170 
171-180 
181-190 
13 
10 
27 
34 
51 
22 
10 
9 
11 
4 
5 
2 
2 
6.5 
5 
13.5 
17 
25.5 
11 
5 
4.5 
5.5 
2 
2.5 
1 
1 
12 
19 
40 
45 
35 
25 
11 
6 
6 
1 
- 
- 
- 
6 
9.5 
20 
22.5 
17.5 
12.5 
5.5 
3 
3 
0.5 
- 
- 
- 
Range 
Mean 
SD 
60-186 
106.9 
24.9 
60-155 
98.7 
19.3 
                            P = 0.00007 significant 
10. RESULTS OF OGTT AT 24-28 WKS 
S.No GCT Random 
Blood glucose
GTT 
 
OGTT 
105 190 165 145 
F 1 hr 2 hr 3 hr  
1 144 138 85 140 126 110 
2 165 150 60 117 96 88 
3 137 128 93 158 122 110 
4 145 138 60 114 126 101 
5 152 140 62 123 102 68 
6 176 150 85 175 128 106 
7 146 112 91 175 140 105 
8 132 120 82 155 132 104 
9 167 146 88 146 103 96 
10 173 155 96 179 111 100 
11 186 140 62 173 89 80  
12 156 130 75 119 108 100 
13 142 136 88 162 113 105 
14 163 146 80 162 126 100 
15 139 116 82 140 130 105  
16 146 113 70 98 96 90 
17 146 117 72 120 78 70 
18 168 142 72 156 122 90 
19 170 142 95 195 170 140 +ve 
20 143 122 87 166 132 100 
21 141 121 81 162 136 98  
22 181 135 91 166 142 98 
23 140 118 89 112 83 72  
24 138 120 119 169 186 132 +ve 
25 136 122 88 170 135 99  
26 143 124 90 165 146 102 
27 137 124 82 140 116 96 
28 154 118 82 130 126 106  
29 133 120 72 170 96 82 
30 150 122 145 205 170 115 +ve 
31 152 123 93 170 122 102 
32 136 122 80 120 76 70 
33 150 120 84 162 115 102 
                
 
  
11 - DETECTION OF GDM BY VARIOUS TESTS 
Test Cut off value 
of Blood 
glucose 
Positive Negative 
No. % No. % 
GCT 140 24 12 176 88 
GCT 130 33 16.5 167 83.5 
RBG 126 16 8 184 92 
GTT  3 1.5 197 98.5 
 
 
 
 
 
 
 
 
 
12 - MANAGEMENT OF DETECTED GDM CASES 
 
Management 
Cases 
No. % 
Diet Control 1 33.33 
Insulin 2 66.7 
 
Tight glycemic control could be achieved by diet control alone 
in one patient.  Other 2 patients required insulin whose requirement 
varied from 15-25 units in 24 hrs. 
Patients were followed with 
1. Meticulous blood glucose control such that in the fasting, blood 
glucose  was <95 mg/dl and 2 hr postprandial blood glucose 
<120mg/dl . 
2. Daily fetal movement count (kick-chart) 
3. Serial ultrasonogram to determine  estimated fetal weight, fetal 
growth profile, congenital anomalies and amniotic fluid index. 
 
 
 
 
DETAILS OF OGTT +VE WOMEN. 
1.     Primi, 31 years of Grade III socio economic status having high 
school education married 6 yrs back (Non consanguinous marriage 
with no family ho diabetes.  Her height was 148 cm and she weighed 
62kg. BMI was 28.30. 
GCT RBG OGTT 
F 1hr 2hr 3hr 
170 142 95 195 170 140 
+ve +ve +ve 
 
               She had PIH in the present pregnancy for which she was 
treated with alphamethyldopa 250mg 2tds.  She was managed with 
diet control alone and she was delivered by LSCS after 37 weeks.   
Indication being mobile breech with PROM with long period of 
infertility.   It was an alive preterm female baby weighing 2kg with 
apgar score 1min 6/10.   Her post operative period was uneventful.  
She came for follow up 6 weeks after delivery and it was found that 
her blood glucose values returned to normal. 
2.      G2 P1L1, 25 yrs of age of grade III socioeconomic status having 
high school education married 3yrs back consanguinous marriage 
with family h/o  diabetes in the mother.  Her height was 157 cm and 
she weighed 65kg. BMI 26.37.  Her previous pregnancy was full 
term normal delivery. 
 
GCT 
 
RBG 
OGTT 
F 1 hr 2 hr 3 hr 
150 122 145 205 170 115 
+ve -ve +ve 
 
       She had h/o recurrent UTI and moniliasis for which treatment 
given.  She was managed with insulin and had spontaneous onset of 
labour after 37wks. An alive term male baby was delivered by outlet 
forceps with episiotomy weighing 3.5kg with 1min Apgar score 
8/10.  Baby had hypoglycemia for which treatment was given.  Baby 
recovered well. Her postpartum period was uneventful.  She came 
for follow up 6 wks after delivery and she was found to have normal 
glucose values. 
3.     G4P1LoA2 belonging to grade IV socioeconomic status had 
primary education married 5 yrs back ( consanguinous marriage) 
with family h/o diabetes in the father.  She had 2 spontaneous 
abortion both certified at 2 and 3 months respectively and in the next 
pregnancy she had sudden IUD at 8 months of gestation.  She had 
h/o PIH in that pregnancy for which she was treated.  Her height was 
156 cm and weighed 62kg BMI 25.47. 
 
GCT 
 
RBG 
OGTT 
F 1hr 2hr 3hr 
138 120 119 169 186 132 
-ve -ve +ve 
 
             She had PIH in the present pregnancy.  She was managed 
with labetalol 100 mg bd and started on insulin and delivered by 
LSCS at 34wks of gestation as the doppler study showed early 
diastolic notch in uterine artery and abnormal high resistance flow in 
umbilical artery.  Indication was BOH with GDM with severe PIH.  
It was an alive preterm male baby weighing 1.8kg with 1min Apgar 
6/10.  On admission to preterm ward baby had respiratory distress 
syndrome and had jaundice for which treatment given.  Baby was 
discharged after 2 wks.  Pt had postoperative wound infection which 
healed with antibiotics.  She reported for follow up 6 weeks after 
delivery and  she was found to have impaired glucose tolerance.  Pt 
was advised lifestyle modification and regular follow up. 
  
Postnatal follow up using 2 hr 75g Oral glucose tolerance test. 
Post natal No of cases in 
patients with GDM 
% 
Reversion back to 
normal 
2 66.67 
Impaired glucose 
tolerance 
1 33.33 
 
         Six weeks, after delivery, 2 reverted back to normal and 1 had 
impaired glucose tolerance. 
 
 
 
 
 
 
 
 
DISCUSSION 
                  A prospective study was conducted in Govt. Rajaji 
hospital during the year 2009.  For this study, 200 randomly selected 
pregnant women in their 24 to 28 weeks of gestation were included.  
50g Glucose challenge Test and Random Blood Glucose was done 
without prior patient preparation in all 200 randomly selected 
pregnant women.  The study was designed to find out whether 50g 
Glucose Challenge Test (or) Random Blood Glucose is better in a set 
up like our hospital to detect gestational diabetes. 
PREVALENCE: 
                  The prevalence of abnormal Glucose Tolerance is highly 
dependent upon ethnicity (Hadden 198527  and Beischer et al 19914)  
Stephen et al in 1981 found in his study that the incidence of 
gestational diabetes lies between 1 to 5%. 
Ranchod et al57 found the prevalence of gestational diabetes in the 
Indian subcontinent 1.6% by applying WHO GTT Diagnostic 
criteria. 
              Ramachandran A56 carried out screening for gestational 
diabetes in 950 patients in southern India showed the prevalence of 
GDM to be 0.56%.  Initially screening test was done with the 50g 
glucose load and values more than or equal to 140mg/dl were 
subjected to 3hr oral GTT.  According to Mudaliar, the incidence of 
diabetes varies from 0.3to0.7%.  In our study of 200 unselected 
pregnant women, when screened between 24-28 weeks of gestation, 
the prevalence of GDM was found to be 1.5%. 
At 24-28 weeks results of the glucose challenge test is as follows: 
              Gabbe et al25 in 1991 concludes that the Glucose Challenge 
Test is the best Screening Test for abnormal Glucose Tolerance.  
The most recent ACOG technical bulletin suggests that 15% of all 
women in a given population would be expected to have abnormal 
GCT. 
             According to Williams when 140 mg/dl is used as threshold, 
14-18% will have positive tests, when 130mg/dl is used as threshold, 
20-25% will have positive tests.  In our study out of 200 randomly 
selected pregnant women when threshold used was 
140mg/dl(7.8mmol/L) 24 women i.e. 12% were screen positive. 
If the cut-off value was reduced to 130mg/dl(7.2mmol/L), 33 women 
(16.5%) were screen +ve.  Therefore in our study among 200 
pregnant women between 24 and 28 weeks of gestation, GCT was 
+ve in 12% of cases. 
                Originally an overall sensitivity of 79% and a specificity 
of 83% was reported by O’Sullivan et al53.  In our study of 200 
randomly selected pregnant women, O’Sullivan’s test had a 
sensitivity of 67% and a specificity  of 89%. 
           Coustan et al11 1993 conducted a study, in which he 
maximized sensitivity by using a 130mg/dl cut-off and he was able 
to increase specificity at the sacrifice of some sensitivity by using a 
140mg/dl cut-off. In our study on 200 randomly selected pregnant 
women, when 140mg/dl was used as cut-off sensitivity was 67% and 
sensitivity increased to nearly 100% when 130mg/dl was used as 
cut-off. 
At 24-28 weeks results of Random Blood Glucose test is as 
follows: 
         Mathai et al, Thomas. T.J. et al46 studied in 121 pregnant 
women with no risk factors using casual plasma glucose estimation 
and found that it had a sensitivity of 63% and specificity was 66%.  
Hadden used random plasma glucose above 120mg/dl irrespective of 
meals as an indication for full testing. 
              In a study by Jardine Brown et al28, a recent specialist UK 
workgroup Report on Diabetes in Pregnancy has suggested that 
women from low-risk populations should be offered a random blood 
glucose estimation at 28 weeks gestation together with further 
random blood glucose measurements whenever glycosuria is 
observed.  If these are >6mmol/L (>108mg/dl in the fasting state or 
2hrs after food, or >7mmol/L (126mg/dl) within 2hrs of food, then a 
GTT should be performed.  Originally a sensitivity of 50% and a 
specificity of 90% was reported.  In our study random blood glucose 
had a sensitivity of 33% and a specificity of 92%. 
       Using these criteria, random blood glucose estimation was done.   
Since almost all women attending our Antenatal O.P came within 2 
hrs of food, 126mg/dl was used as the cut-off value for random 
blood glucose in our study.  Out of 200 pregnant women screened, 
16 women (8%) were screen +ve.  Therefore in our study among 200 
pregnant women between 24 and 28 weeks of gestation, Random 
blood glucose was +ve in 8% of cases, OGTT confrmed the 
diagnosis in 6.25% of these positive tests. 
 
 
Oral Glucose tolerance test 
     OGTT was done on all women who were screen positive the 
results were interpreted using NDDG criteria. 
    1 patient had GCT positive, random blood glucose positive and 
OGTT positive, second pt had GCT positive, random blood glucose 
negative, but OGTT positive.  Third pt had GCT negative, random 
blood glucose negative, but OGTT positive.  
         According to the 1986 ACOG technical bulletin, 15% of those 
undergoing 3hr OGTT could be anticipated to have an abnormal 
result.  In our study 10% of those undergoing 3hr OGTT had an 
abnormal result. 
        In the Toronto-tri hospital study, women who had “borderline”  
GDM ( met carpenter and coustan’s criteria but not NDDG criteria) 
and had one abnormal value using the NDDG criteria,  had twice the 
rate of macrosomia as women who had normal glucose testing (28% 
versus 13%). 
             So 3hr OGTT was done on all screen positive women and 
the results were interpreted using NDDG ( National Diabetes Data 
Group) criteria.  Out of this 3 women were found to have gestational 
diabetes, among them 2 had family history of diabetes and one had 
h/o  sudden IUD 
UNIVERSAL SCREENING VS SELECTIVE SCREENING 
        According to American college of obstetrics and Gynaecology 
all pregnant patients should be screened for gestational diabetes.  But 
according to American diabetes association, screening should be 
done for women with risk factors alone because of cost-benefit 
considerations. 
     In a study by Danilenko Dixon DR, van winter J.T. nelson Riet 
al17 applying ADA critieria, 3% of gestational diabetics would have 
gone undiagnosed. 
     In a study by coustan et al11 on 6214 women if screening is done 
based on risk factors alone, 35% of all cases of a GDM would be 
missed. 
     Howard et al recommended screening with 50g oral glucose load 
followed by a 3hr GTT for women with risk factors alone and found 
that 30-50% of women with gestational diabetes were overlooked. 
Dradi, Maraldi.C Confirmed that O’Sullivan’s GCT at 24-28 weeks 
of gestation in all pregnant women is a must since GDM is often 
pauci or asymptomatic which is associated with an increase of 
maternal fetal and neonatal morbidity plus an increased risk of later 
overt diabetes mellitus in the mother. 
     Baxi L, Singh. S, Sacks, D2 concluded that plasma glucose 
obtained 1hr after 50g oral glucose challenge is the best GDM 
Screening Test.   
      If only women with high risk factors are screened approximately 
35% of GDM patients will be missed.  So screening should be 
universal.  Universal screening for GDM is justified by morbidity 
reduction, protocols simplicity and ease. 
MATERNAL OUTCOME 
Age: 
     Moses et al55 in his study showed that age more than 30yrs is 
present in 8.5% of GDM Patients and age younger than 21 years is 
present only in 0.7% of GDM Patients. 
     In our study age more than 30yrs was present in 33.33% of GDM 
Patients and age younger than 21yrs was not present in any GDM 
patient. 
Parity 
     Pyke DA et al55found that the incidence of diabetes increased 
with increasing parity.  But according to recent reports parity has no 
predictive value for diabetes and is unlikely to play an etiological 
role. 
     In our study the incidence of GDM was slightly higher in multi 
gravidas. 
BMI 
             Serirat et al 1992 in a study found that Obesity was present 
in 26.5% of patients with GDM.  Landon and colleagues (1994) and 
zhang and co-workers (1995) found that the risk of gestational 
diabetes was increased in women with truncal Obesity.  (Williams 
Obstetrics) 
         In our study pts with GDM were in the Overweight category 
BMI 25-29.9 
Family History: 
       Serirat et al68 in 1992 has shown that family H/O diabetes is 
present in 23.1% of Patients with abnormal glucose tolerance. 
       Moses et al49 in 1995 has shown that family H/O diabetes is 
present in 11.6% of patients with GDM. 
     In our study family H/O diabetes Mellitus was present in 66.66% 
of Patients with GDM. 
 
IN ANTENATAL PERIOD: 
PIH: 
         Suhonen and Terano 64 in 1993 reported the incidence of PIH 
and pre-eclampsia to be 2 times more common among GDM patients 
than controls (19.8%Vs 10%). 
         Siddigi T, Rossen.B, Mimouri F et al61 in their study found 
incidence of PIH in GDM to be approximately 15% compared to 
7.7% in controls. 
     In our study PIH was found in 66.66% of pregnant diabetic 
patients. 
HYDRAMNIOS: 
        Biggio et al in 1999 reported that hydramnios occurs in 20 % of 
diabetic pregnancies.  Rosenn et al74 found incidence of hydramnios 
to be 26.4% in their study. 
       In our study hydramnios was found in 33.33% of GDM Patients. 
MANAGEMENT: 
      Langer.O, Rodri Guez. D.A, Xenakis E.M. et al43 30-60% of 
patients with GDM were treated with insulin.  In our study 66.66% 
of GDM Patients were treated with Insulin. 
 
IN THE INTRA-PARTUM PERIOD 
 Time of Delivery: 
     In a study by Goldman et al, pre-term delivery occurred in 9.4% 
of patients with GDM compared to 6.9% in controls. Preterm 
delivery is more common in women with pre-gestational diabetes 
than in women with GDM. 
     In our study 66.66% of  patients with GDM had Preterm 
Delivery. 
Mode of delivery 
     Goldman et al24 in the study found caesarian section rates to be as 
high as 35% compared to 22% in normal controls. 
     Hawthorne G.Robson et al32 in her study found caesarian section 
rates as high as 60-65%.   In our study caesarian secion rates was 
almost 67%. 
In the Post-Partum Period 
     Jacobson and cousins et al27 in a study found post-caesarian 
infection in patients with GDM to be 12.4% compared to 5.9% in 
controls. 
 
 
Maternal Mortality 
     Maternal deaths have become rare in women with diabetes, 
although as emphasized by cousins (1987), mortality is increased 10-
fold, most often as a result of ketoacidosis, underlying Hypertension, 
preeclampsia, pyelonephritis and patients with coronary artery 
disease (class H). 
     In our study there was no maternal mortality. 
FETAL OUTCOME 
Birth Weight: 
     Spellacy, W.N.Mills and winger.A65 found that macrosomia is 
present in 50% of pregnancies in patients with GDM.  But lowering 
of birth weight by treatment has been shown in many studies 
including those of O’Sullivan’s et al. 
    In our study one patient had delivered a baby weighing 3.5kg  
Neonatal Complications: 
Hypoglycemia: 
     Gabbe et al25observed that 99 babies out of 257 infants of diabetic 
mothers(39%) became hypoglycemic after delivery.  According to 
James High risk pregnancy, the frequency of hypoglycemia is 18-
49%. 
     In our study Hypoglycemia was present in 33.33% of babies born 
to patients with GDM. 
Hypocalcaemia: 
     Marshall R.E in his study found the incidence of Hypocalcaemia 
in infants of diabetic mothers to be 50% . Kitzmiller J. Cloherty, J et 
al39 found that the incidence of  hypocalcaemia in infants of diabetic 
mothers to be 5-22% (Michael de Swiet). 
     In our study, hypocalcaemia was not found in any of the babies. 
Hyperbilirubinemia: 
     Beard and lowy et al3 found that the incidence of jaundice in 
infants of diabetic mothers to be 20% . 
     In our study Hyperbilirubinemia was found 33.33% of babies 
born to patients with GDM. 
Respiratory Distress Syndrome: 
             Several studies agree that in well controlled diabetic patients 
delivered at term, the risk of RDS is no higher than that observed in 
the general population (10-15%). 
            In our study RDS was present in 33.33% of babies born to 
patients with GDM. 
 
Perinatal Mortality: 
     All the 3 women with GDM, had good fetal outcome.  Even the 
babies who had complications recovered well and there was no 
perinatal mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STATISTICAL DATA 
Validity of Glucose Challenge test 
     Statistical attributes of Glucose challenge test as a screening test 
for the detection of Gestational diabetes were analyzed and found as 
follows: 
Cut off > 140 mg / dl 
GCT 
(>140mg/d1) 
OGTT 
Positive Negative 
No. % No. % 
Positive (24) 2 8.3 22 91.7 
Negative (176) 1 0.6 175 99.4 
True positive  =     2 
False positive =   22 
True Negative = 175 
False  negative  =    1 
Sensitivity  =  67% 
Specificity  =  89% 
Accuracy    = 89% 
Positive predictive value    =   8% 
Negative predictive value     = 99%           
  P = 0.0385 significant. 
Mean Blood glucose values  106.9mg 
Standard  deviation 24.9. 
 
Cut off > 130 mg / dl 
GCT 
(>130mg/dl) 
OGTT 
Positive Negative 
No. % No. % 
Positive (33) 3 9.1 30 90.9 
Negative 
(167) 
- - 167 100 
 
True positive  3 
False positive 30 
True Negative 167 
False negative Nil 
Sensitivity 100% 
Specificity 85% 
Accuracy  85% 
Positive predictive value  9% 
Negative predictive value  100% 
                       P = 0.0041 significant. 
prevalence  1.5% 
 
INFERENCE: 
     Therefore reducing the threshold of GCT to >130mg/dl resulted 
in increase in sensitivity thereby yielding a higher diagnostic result. 
Validity of Random Blood Glucose test 
     Statistical attributes of Random Blood Glucose test as a screening 
test for the detection of Gestational diabetes were analyzed and 
found as follows: 
RBG 
(>126mg/dl) 
OGTT 
Positive Negative 
No. % No. % 
Positive (16) 1 6.3 15 93.8 
Negative (184) 2 1.1 182 98.9 
True positive  1 
False positive 15 
True Negative 182 
False negative 2 
Sensitivity 33% 
Specificity 92% 
Accuracy  92% 
Positive predictive value  6% 
Negative predictive value  99%  
                       P = 0.2223 Not  significant. 
Mean Blood glucose values  98.7 
 
Standard  deviation 19.3. 
Screening test Sensitivity % Specificity % PPV % NPV % 
GCT(<140mg/dl) 67 89 8 99 
GCT(<130mg/dl) 100 85 9 100 
RBG(<126mg/dl) 33 92 6 99 
 
INFERENCE: 
     GCT had a sensitivity of 67% and hence is for superior to 
Random blood glucose estimation.   
GDM and family history of Diabetes 
Family History of 
DM 
OGTT 
Positive Negative 
No. % No. % 
Present (26) 2 7.7 24 92.3 
Absent (174) 1 0.6 173 99.4 
 
 X2 =3.69 
 P =0.045(Significant) 
 
 
  
GDM and Quantitative variables 
Variable Value for cases  
‘p’ GDM cases Non GDM cases
Mean SD Mean SD 
Age 27.3 4.0 24.1 3.3 0.1443(Not 
significant) 
Weight 63 1.7 49.1 8.5 0.0098(Significant)
BMI 26.7 1.4 21.4 3.6 0.0159(Significant)
a)GCT 
b) RBG 
152.7 
128 
 
16.2 
12.2 
106.2 
98.2 
24.3 
19.0 
0.0104(Significant)
0.0139(Significant)
 
 
 
 
 
 
 
SUMMARY 
 
1. In our study of 200 unselected pregnant women, prevalence of 
gestational diabetes was found to be 1.5%. 
2.  In detecting gestational diabetes in our population, the 50g 
Glucose Challenge Test had a sensitivity of 67% and 
specificity of 89% whereas Random Blood Glucose test had a 
sensitivity of 33% and a specificity of 92% .  Hence it was 
found that Glucose Challenge Test was far superior to Random 
Blood Glucose estimation. 
3.  If the threshold in GCT was taken as 140 mg/dl, sensitivity 
was 67% whereas if the threshold in GCT was taken as 
130mg/dl, the sensitivity was increased to nearly 100%. 
4.  Both Glucose challenge Test and Random Blood Glucose test 
do not require any prior patient preparation. 
5.  Oral Glucose Tolerance Test is the Gold Standard Diagnostic 
test for the diagnosis of gestational diabetes. 
6.  Universal screening for gestational diabetes has to be done 
since selective screening of women with high risk factors 
alone is likely to miss more than 1/3rd of cases with gestational 
diabetes  
7.  In a population like ours, universal screening with 50g 
Glucose Challenge Test should be performed on all pregnant 
women between 24 and 28 weeks of gestation. 
 
              Hence early detection of gestational diabetes and effective 
management to maintain optimal blood glucose levels will 
drastically reduce maternal morbidity due to gestational diabetes and 
will bring about a definite reduction in perinatal mortality rate. 
 
 
 
 
 
 
 
 
 
  
 
CONCLUSION 
 
     Universal screening for GDM has to be done with Glucose 
Challenge test to detect Gestational diabetes early irrespective of the 
presence or absence of risk factors. 
 All detected GDM patients have to be closely monitored for 
strict glycemic control throughout pregnancy for optimal maternal 
and neonatal outcome. 
 
 
 
 
 
 
 
 
PROFORMA 
Name of the patient :     Date : 
 
Husband’s name  :     Age  :  
OP No.   : 
Address   : 
Socioeconomic Status : 
Educational Qualification: 
Obstetric code 
LMP 
EDD 
Marital Status 
Married since how many years. 
Family history of DM 
H/o preexisting  Diabetes 
 
H/o Risk factors in present pregnancy 
 h/o recurrent UTI 
 h/o moniliasis 
 h/o PIH 
 h/o Hydrammios 
 h/o Glycosuria 
 h/o Congenital malformations 
 
H/o Risk factors in past pregnancy 
  h/o spontaneous abortion 
  h/o preterm delivery 
  h/o Still birth 
  h/o sudden neonatal death 
  h/o difficult forceps 
  h/o fetal macrosomia 
h/o previous PIH 
h/o previous congenital anomalies. 
 
CLINICAL EXAMINATION 
  Height  
  Weight 
  Gestational age 
 
LABORATORY RESULT 
  Blood glucose level following GCT 
  Random Blood glucose 
  OGTT values 
 
INTERPRETATION. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
 
GCT   Glucose Challenge test 
RBG   Random Blood glucose 
OGTT  Oral Glucose Tolerance Test 
FPG   Fasting Plasma Glucose 
GDM  Gestational Diabetes Mellitus 
PIH   Pregnancy induced hypertension 
BMI   Body mass Index 
BOH   Bad obstetric history 
LSCS  Lower segment caesarean section 
UTI   Urinary tract infection 
LMP   Last menstrual period 
EDD   Expected date of delivery 
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Name OP No Obstetric Code F 1hr 2hr 3hr
1 Pandisweeri 15459 Primi 23 Father Diabetic 49 150 19.6 90 86
2 Priya 9369 G3P1L1A1 23 h/o Abortion 45 142 22.3 96 90
3 Sikandar Maa 17788 G2P1L1 26 - 39 153 16.7 86 100
4 Sharmila 19281 G2P1L1 31 Father Diabetic 43 158 17.2 84 72
5 Rani 9486 G2P1L1 24 Mother Diabetic 38 152 16.4 78 84
6 MANONMANI 15622 G2P1L1 28 Father Diabetic 41 141 20.6 80 93  
7 UMADEVI 14868 Primi 21 - 43 150 19.1 68 74
8 PANDISELVI 15079 G3P1L1A1 25 h/o Abortion 50 153 21.4 98 90
9 MUTHUMARI 22559 G3P2L1 29 h/o Macrosomia, h/o Sudden IUD 60 154 25.3 90 102
10 GEETHA 9466 G2P1L1 25 - 60 147 27.8 100 94
11 DEVI 20453 Primi 25 - 38 140 19.4 115 120
12 PARVATHY 11009 G2P1L1 24 - 52 149 23.4 61 80
13 SHALINI DEVI 28223 G3A2 26 h/o Abortion 51 142 25.3 115 102
14 LAKSHMI 28237 G3P2L1 27 h/o neonatal death,h/o recurrent UTI 43 146 20.2 126 130
15 BOTHAI AMMAL 28225 G2P1L1 25 PIH 56 155 23.3 99 94
16 MAHESWARI 28217 Primi 24 - 62 145 29.5 99 89
17 MUTHULAKSHMI 28216 Primi 20 - 42 143 20.5 87 82
18 ESWARI 28233 G2P1L1 26 Father Diabetic, PIH 40 145 19.0 101 96
19 MARAGATHAM 28437 G2P1L1 22 - 51 148 23.3 83 86
20 PANDISELVI 28438 G2P1L1 21  60 143 29.3 66 72
21 MEENAKSHI 28434 Primi 28 - 41 150 18.2 106 101
22 YASMIN 28455 Primi 20 - 49 146 23.0 64 72
23 SHAMBAGAM 18038 G5P4L1 27
h/o Abortion, h/o Sudden IUD, h/o Pre term 
Delivery, h/o recurrent UTI 40 145 19.0 144 138 85 140 126 110
24 KALEESWARI 28440 G2P1L0 22 h/o Stillbirth 50 148 22.8 68 72
25 THASLEEMA 11058 Primi 20 Father Diabetic, PIH, Glycosuria 51 146 23.9 165 150 60 117 96 88
26 JAYA 11661 Primi 23 - 70 157 28.4 104 99
27 DEVI 11662 Primi 20 - 43 157 17.4 68 62
28 RATHIKA 11670 G2A1 27 h/o Abortion 66 158 26.4 76 74
OGTT 
S.No Age Weight Height BMIRisk Factors GCT RBG
29 HEMALATHA 11669 G2P1L1 29 PIH 58 154 24.5 111 120
30 ANEES PATHMA 11668 G2P1L1 21 Recurrent UTI 37 146 17.4 91 72
31 TAMILARASI 6431 Primi 21 - 50 146 23.5 128 116
32 KARISHMA 10517 G2P1L1 26 - 51 150 22.7 122 108
33 GOKILA RANI 11664 G2P1L0 27
Father Diabetic, h/o Congenital Malformation
Moniliasis 70 153 29.9 96 92
34 RAKKU 11708 Primi 19 - 51 148 23.3 94 90
35 SHANTI 11709 G2A1 24 h/o Abortion 52 148 23.7 100 86
36 DEVI 11713 G2P1L1 30 - 49 148 22.4 107 98
37 ANGALEESWARI 11727 Primi 20 - 41 149 18.5 137 128 93 158 122 110
38 SEKKI 11725 G2P1L1 22 - 49 152 21.2 119 112
39 JAYAPRIYA 7868 Primi 18 - 51 149 23.0 101 96
40 PODUMPONNU 9722 Primi 31 - 53 147 24.5 111 96
41 KAMESWARI 11758 G2P1L1 20 Both Diabetic, h/o Macrosomia 56 160 21.9 105 115
42 LAKSHMI 11314 G2P1L1 20 Moniliasis, Glycosuria 42 151 18.4 145 138 60 114 126 101
43 BACKIALAKSHMI 11760 G2P1L1 24 Glycosuria 52 153 22.2 152 140 62 123 102 68
44 RAJALAKSHMI 11769 G2P1L1 23 h/o Macrosomia 46 152 19.9 111 106
45 MATHA 9525 Primi 25 - 41 152 17.7 107 101
46 LATHA 19105 G2P2L1 24 PIH 56 150 24.9 68 70
47 VASANTHA 8221 G2P1L1 23 - 46 156 18.9 176 150 85 175 128 106
48 KATHIJA BEEVI 20484 G2P1L1 23 Twins, h/o Macrosomia 53 155 22.1 80 82
49 PANDEESWARI 8311 Primi 22 Heat Disease Compl 51 163 19.2 146 112 91 175 140 105
50 RAJALAKSHMI 20507 G2P2L1 26 - 38 152 16.4 113 106
51 KAVITHA 29512 G2A1 20 h/o Abortion 60 158 24.0 103 99
52 IRULI 9080 G2P1LO 27 h/o Sudden IUD 45 158 18.0 96 93
53 MANIMEKALAI 11847 G2A1 20 h/o Abortion 40 148 18.3 132 120 82 155 132 104
54 KAMATCHI 11849 G3P2L2 20 - 40 150 17.8 97 88
55 MURUKESWARI 11698 G2A1 22 Mother Diabetic, h/o Abortion 56 160 21.9 62 60
56 PANCHAVARNAM 11900 Primi 22 - 48 146 22.5 111 102
57 PONMAYIL 11952 G2P1L1 30 - 48 146 22.5 167 146 88 146 103 96
58 CHITRA 11016 G2P1L1 32 - 51 150 22.7 173 155 96 179 111 100
59 CHITRA 10551 Primi 21 - 39 147 18.0 101 96
60 LAKSHMI 11905 G2A1 22 h/o Abortion 46 143 22.5 89 88
61 PODUMPONNU 11947 G2P1L1 24 - 46 150 20.4 83 80
62 DEVI 11963 G2P1L1 24 - 45 152 19.5 90 84
63 MURUKESWARI 11967 Primi 24 - 44 152 19.0 82 70
64 MEENA 12003 Primi 20 - 49 158 19.6 103 88
65 NACHAMMAL 12008 G2P1L1 25 Glycosuria 52 154 21.9 129 120
66 BRINDHA 84233 Primi 23 - 50 150 22.2 108 101
67 ANGALEESWARI 12009 G2P1LO 27 Mother Diabetic, Glycosuria, h/o Sudden IUD 60 153 25.6 186 140 62 173 89 80
68 VEERAMMAL 12012 G2P1L1 29 Father Diabetic, Glycosuria 57 156 23.4 156 130 75 119 108 100
69 RAMJAN BEGAM 11930 Primi 21 Both Diabetic, Congential Malformation 44 154 18.6 108 96
70 PONNU MUNIYAMMAL 11202 G2P1L1 22 Twins, Hydramnios 42 147 19.4 99 90
71 KALAISELVI 12024 Primi 20 - 44 155 18.3 101 98
72 UMA 12026 G2P1L1 24 47 153 20.1 76 70
73 SIVAGAMI 12027 G2P1L1 24 PIH 40 144 19.3 118 102
74 PANCHU 12036 G2P1L1 24 58 141 29.2 108 106
75 RADHA 12040 G2P1L1 27 39 152 16.9 77 70
76 SUBATHRA DEVI 7657 G2P1L1 22 - 48 148 21.9 89 82
77 SAKTHI MAI 12050 Primi 26 - 43 156 17.7 112 107
78 KALAIVANI 10459 Primi 23 - 43 152 18.6 123 118
79 LINGESWARI 12100 G2P1L1 27 PIH, Glycosuria 57 152 24.7 142 136 88 162 113 105
80 MALATHI 12111 G3P2LO 32
Congential Malformation, h/o Pre term
Delivery, h/o Stillbirth 56 156 23.0 93 90
81 DURGADEVI 30085 Primi 22 Glycosuria 44 149 19.8 163 146 80 162 126 100
82 MALIGA 9618 Primi 30 - 44 159 17.4 123 118
83 NOORSHANT NISHA 8134 G2P1L1 27 Glycosuria 44 161 17.0 139 116 82 140 130 105
84 VIJAYARANI 11165 G3P1L1A1 24 h/o Abortion, h/o Macrosomia 53 151 23.2 110 101
85 RAJESWARI 12129 G4P3L1 21
Glycosuria, h/o Sudden IUD, h/o Stillbirth, h/o
Outlet Forceps 66 150 29.3 146 113 70 98 96 90
86 MANIPRABHA 12130 G2P1L1 24 Glycosuria 57 143 27.9 146 117 72 120 78 70
87 MAHESWARI 5832 Primi 21 Glycosuria 46 142 22.8 168 142 72 156 122 90
88 KANIMOZHI 25914 Primi 23 Father Diabetic 46 157 18.7 86 80
89 MEENA 10755 Primi 20 - 46 155 19.1 83 77
90 NAGESWARI 12138 Primi 23 50 150 22.2 104 87
91 PRIYADHARSINI 12146 G2P1L1 25 - 59 155 24.6 128 120
92 SASIKALA 10513 G2P1L1 27 h/o Outlet Forceps 40 151 17.5 60 66
93 SHANTI 12144 G2P1L1 25 - 51 152 22.1 97 92
94 SUNDHARI 29911 Primi 31 Glycosuria, Hydramnios, PIH 62 148 28.3 170 142 95 195 170 140
95 AMBIKA 12240 G2P1L1 25 - 56 157 22.7 106 102
96 RUBINI 12244 Primi 18 - 47 148 21.5 89 82
97 SATHYA 12250 Primi 19 Glycosuria 47 165 17.3 143 122 87 166 132 100
98 SURIYA 12253 Primi 19 - 61 157 24.7 101 97
99 CHANDRA 10539 G3P3L2 31 46 150 20.4 98 90
100 SUBERIA BANU 12291 Primi 20 - 57 153 24.3 141 121 81 162 136 98
101 RUKMANI 9283 Primi 23 - 48 165 17.6 94 92
102 GANDHIMATHI 6583 Primi 30 - 54 148 24.7 181 135 91 166 142 98
103 VANITHA 8251 Primi 25 0 72 156 29.6 104 88
104 VANITHA 12303 Primi 32 0 52 149 23.4 140 118 89 112 83 72
105 SUGANYA 11375 G3P1LO 20 h/o Abortion, h/o Congenital malformation 48 146 22.5 81 62
106 MARUTHAYI 12348 Primi 24 0 40 152 17.3 82 68
107 RAJESWARI 91636 G2P1L1 25 PIH 50 150 22.2 106 92
108 RAMAPRIYA 5489 Primi 21 0 38 146 17.8 92 86
109 SUBHASHINI 11621 Primi 20 0 56 152 24.2 88 80
110 MARY PUSHPA RANI 42812 G4P1L0A2 28
Father Diabetic, PIH, Glycosuria,  h/o 
Abortion, h/o Sudden IUD, h/o Previous PIH 62 156 25.5 138 120 119 169 186 132
111 MALARKODI 8839 G2P1L1 24 Mother Diabetic 46 146 21.6 107 101
112 VEERAMMAL 11129 Primi 21 0 52 158 20.8 70 62
113 SABIA BEGAM 9079 G2P1L1 24 0 48 148 21.9 109 101
114 RAHMAT BEEVI 10185 Primi 21 0 46 152 19.9 136 122 88 170 135 99
115 MAHALAKSHMI 23193 G2P1L1 24 0 45 148 20.5 104 100
116 DHANALAKSHMI 9367 G2P1L1 26 0 60 156 24.7 86 82
117 SATHYA 12393 G2A1 23 Mother Diabetic,h/o Abortion 40 162 15.2 143 124 90 165 146 102
118 PARVATHY 12394 G2P1L1 21 0 48 150 21.3 137 124 82 140 116 96
119 CHINNAPILLAI 12397 G4P3L1 25 h/o Sudden IUD 40 150 17.8 154 118 82 130 126 106
120 KRISHNAVENI 8312 G2P1L1 24 Glycosuria 63 150 28.0 133 120 72 170 96 82
121 ANNALAKSHMI 41478 G4P1L1A2 23 h/o Abortion 68 154 28.7 125 116
122 VANI 12293 G2P1L1 26 Father Diabetic 46 148 21.0 107 99
123 VELUMANI 8988 G2A1 26 h/o Abortion 50 152 21.6 90 86
124 PATHLA BANU 92168 Primi 19 51 155 21.2 108 98
125 MALIGA 20116 Primi 28 59 142 29.3 96 90
126 KAVITHA 11233 Primi 20 Mother Diabetic 70 160 27.3 89 82
127 OYYAMMAL 12211 G4P2L2A1 35 h/o Abortion 60 160 23.4 89 82
128 KALEESWARI 30772 Primi 20 PIH 41 142 20.3 93 84
129 AMUDHA 12315 G2P1L1 26 77 161 29.7 97 86
130 SHARMILA 10642 G2A1 24 h/o Abortion 67 160 26.2 104 92
131 CHANDRA 9017 G3P2L2 27 h/o Macrosomia 56 152 24.2 83 80
132 KAVITHA 11954 G3P2L2 23 h/o Macrosomia 40 158 16.0 103 92
133 KAVITHA 11748 Primi 23 35 150 15.6 96 88
134 PANDIAMMAL 9550 G2P1L1 23 h/o Macrosomia 50 151 21.9 105 100
135 LAKSHMI KALA 11063 Primi 25 Father Diabetic 48 155 20.0 84 76
136 MUTHU SARASWATHI 11464 Primi 23 63 153 26.9 103 97
137 INDRA 30673 Primi 30  50 159 19.8 111 101
138 MUTHULAKSHMI 1209 G3P1L1A1 30 h/o Abortion 50 161 19.3 106 102
139 VIJAYA 8255 G4P2L1A1 23 h/o Abortion, h/o neonatal Death, PIH 50 155 20.8 98 92
140 AYAMMAL 14922 G2P1L1 30 41 148 18.7 97 94
141 SHANTI 3509 Primi 23 Father Diabetic 50 142 24.8 78 72
142 SUMATHI 12126 Primi 23 50 155 20.8 104 96
143 CHITRA 12140 Primi 25 50 152 21.6 108 98
144 MAHALAKSHMI 12385 G3P1L1A1 29 h/o Abortion 46 148 21.0 96 100
145 MEENAKSHI 12331 Primi 23 Hydramnios 40 144 19.3 106 108
146 SHANTI 5799 G4P2LOA1 26 Hydramnios, h/o Abortion, h/o Stillbirth 45 150 20.0 106 102
147 POORNIMA 10643 G2P1L1 23
Mother Diabetic, Recurrent UTI, Moliasis, 
Glycosuria 65 157 26.4 150 122 145 205 170 115
148 SIVAPOOMATHI 30598 G2P1L1 21 h/o Macrosomia, PIH 45 145 21.4 108 101
149 LAKSHMI 12347 G4P3LO 27 h/o Sudden IUD 58 149 26.1 152 123 93 170 122 102
150 SELVI 31188 G2P1L1 24  45 142 22.3 87 82
151 NAGALAKSHMI 93269 Primi 26 Hydramnios, Mother Diabetic 40 150 17.8 107 97
152 JYOTHI 11700 Primi 23 56 156 23.0 112 104
153 TAMILARASI 12514 G2P1L1 23 50 152 21.6 106 96
154 VIJAYALAKSHMI 6211 G2P1L1 26 Heart Diseases Compl, h/o Outlet Forceps 63 150 28.0 109 101
155 MAHALAKSHMI 10816 G2P1L1 22 53 150 23.6 102 92
156 SATHYA 10841 G2P1LO 20
Hydramnios, Father Diabetic, h/o neonata
death 53 143 25.9 94 96
157 AYISHA 8290 G2P1L1 23 50 150 22.2 80 72
158 ESWARI 7267 G4P2L1A1 25 h/o Abortion, Epilepsy Compl 48 148 21.9 115 105
159 ISWARIYA 30198 Primi 21 55 153 23.5 118 102
160 SOBHIA 30188 Primi 24 Anaemia 50 158 20.0 98 90
161 CHELLAMAL 11729 G2P1L1 30 52 151 22.8 109 96
162 JAYALAKSHMI 12526 G2A1 23 h/o Abortion 40 154 16.9 95 90
163 VASUKI 12525 Primi 20 Glycosuria 40 162 15.2 136 122 80 120 76 70
164 MALIGA 12523 Primi 22 35 148 16.0 82 80
165 GOMATHI 12525 Primi 26 45 155 18.7 71 82
166 KOWSALYA 12527 Primi 19 PIH 45 151 19.7 108 101
167 MANOHARI 5972 Primi 32 55 144 26.5 72
168 BOWSIYA BEGAM 8738 G3P2L2 29 62 156 25.5 92 90
169 THAVAMANI 12278 G2P1L1 24 Glycosuria 62 152 26.8 110 101
170 SIVAGAMI 6536 G4P1L1A2 25 h/o Abortion 35 148 16.0 69 62
171 BHAVANI 10860 G2A1 26 h/o Abortion 46 150 20.4 98 96
172 BHUVANESWARI 12529 Primi 23 PIH 38 150 16.9 150 120 84 162 115 102
173 ANUSUYA 12530 G2A1 27 h/o Abortion, Hydramnios, Glycosuria 42 152 18.2 124 116
174 KRISHNAVENI 12534 G2P1L1 29 55 151 24.1 116 112
175 KALA 12538 G3P1L1A1 25 h/o Abortion 50 148 22.8 104 94
176 MAYIL 12539 G2A1 20 h/o Abortion 55 152 23.8 102 92
177 VIMALA 8553 Primi 19 PIH 40 148 18.3 99 94
178 ESWARI 12532 Primi 19 Hyramnios, Congenital Anomaly 42 154 17.7 92 88
179 USHA NANDHINI 11579 G2P1L1 24 73 158 29.2 68 74
180 PANDEESWARI 12543 Primi 22 38 146 17.8 108 110
181 RANI 12550 Primi 28 Mother Diabetic 44 151 19.3 102 98
182 SELVI 12548 G2A1 20 h/o Abortion 48 160 18.8 88 86
183 SUNDHARESWARI 12547 Primi 22 40 156 16.4 98 92
184 SIVANDEESWARI 12546 Primi 27 46 151 20.2 112 101
185 BANU 8745 Primi 23 35 147 16.2 101 86
186 KALEESWARI 11778 G3P1L1A1 23 h/o Abortion, h/o Macrosomia 55 156 22.6 119 106
187 SUMATHI 9274 G3P1L1A1 33 h/o Abortion 32 150 14.2 101 92
188 KRISHNAVENI 12563 Primi 21 56 164 20.8 70 68
189 SELVI 12634 G3P2L2 25 40 142 19.8 107 103
190 PANCHAVARNAM 12635 G2P1LO 22 h/o neonatal death 35 150 15.6 113 103
191 MEENA 12644 G2P1L1 23 h/o Macrosomia 42 142 20.8 109 102
192 SUDHA 11665 Primi 23 PIH 42 152 18.2 120 110
193 DURGADEVI 11427 Primi 20 42 147 19.4 97 88
194 PANDISELVI 12129 G2P1L1 27 42 154 17.7 119 111
195 INBADURGA 2469 G2P1L1 27 h/o Previous PIH 56 156 23.0 86 82
196 USHA 9434 G2P1L1 27 40 143 19.6 113 103
197 SASIKALA 31067 Primi 23  40 147 18.5 122 120
198 OMSAKTHI 9992 Primi 20 Mother Diabetic 45 148 20.5 120 115
199 VANITHA 4421 G3P1LOA1 24
Father Diabetic, h/o Abortion, h/o Outlet
Forceps 56 161 21.6 106 99
200 RAJADEIVAKANI 12472 G2A1 26
PIH, Hyramnios, Congenital Anomaly, h/o 
Abortion 45 156 18.5 97 92
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